Mereo BioPharma Group plc (AIM:MPH)

Market Cap	32.98M -83.5%
Revenue (ttm)	n/a
Net Income	-21.18M
EPS	-0.13
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,264
Open	26.50
Previous Close	27.00
Day's Range	26.00 - 26.20
52-Week Range	13.00 - 60.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an o...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 39
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: MPH

Financial Performance

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 25, 2026

Data Sources Report a data error